• Cefiderocol In Vitro Activity Against Resistant P. aeruginos

  2026-07-29

  This study provides a comprehensive analysis of cefiderocol’s in vitro efficacy against European Pseudomonas aeruginosa and Acinetobacter spp., including strains resistant to meropenem and β-lactam/β-lactamase inhibitor combinations. The findings inform laboratory research and clinical decision-making by highlighting cefiderocol’s high activity profile and resistance mechanisms in a large contemporary isolate set.

• ICG001: Advancing Wnt/β-Catenin Modulation from Bench to Bed

  2026-07-29

  This thought-leadership article explores the mechanistic, experimental, and translational dimensions of ICG001, a selective Wnt/β-catenin pathway inhibitor. By dissecting its role in β-catenin/CBP interaction and contextualizing its value against recent research on bone regeneration, fibrosis, and cancer, we provide strategic insight for translational researchers. This piece also contrasts ICG001’s applications with other modulators, outlines protocol parameters, and concludes with an outlook on the future landscape of Wnt signaling interventions.

• Cefoperazone Sodium Salt: β-Lactamase-Stable Activity Profil

  2026-07-28

  Cefoperazone sodium salt is a semisynthetic cephalosporin antibiotic with robust antibacterial activity against gram-negative bacilli and high resistance to β-lactamase hydrolysis. It demonstrates low MIC values in vitro and is used extensively in research models of bacterial infection and antibiotic resistance.

• MLN8237 (Alisertib): Precision Targeting of Aurora A in Canc

  2026-07-28

  Explore how MLN8237 (Alisertib), a selective Aurora A kinase inhibitor, advances cancer biology by enabling high-specificity dissection of mitotic mechanisms and apoptosis in tumor cells. This article delivers a unique, protocol-rich perspective grounded in cutting-edge assay innovations.

• Comparative Antibacterial Profiles of β-Lactams: Insights fr

  2026-07-27

  Cullmann et al. conducted a landmark study comparing the antibacterial activity of N-formimidoyl thienamycin (MK0787) with several advanced β-lactam antibiotics, including cefoperazone, across a diverse panel of drug-resistant clinical isolates. The findings clarify spectrum strengths, β-lactamase stability, and bactericidal behavior among modern cephalosporins and carbapenems, informing researchers’ choices for resistance modeling and antimicrobial assay design.

• Cardiogreen (Indocyanine Green): Applied Protocols and Innov

  2026-07-27

  Cardiogreen (Indocyanine Green) stands apart as a vascular imaging dye and photosensitizer, enabling both high-fidelity diagnostics and advanced photodynamic therapy. This article unpacks protocol-level guidance, troubleshooting, and recent breakthroughs in leveraging Cardiogreen for quantitative measurement and immuno-oncology.

• Hexetidine (NSC-17764): Mechanistic Insights and Clinical Tr

  2026-07-26

  Explore the multifaceted antimicrobial actions of Hexetidine (NSC-17764), including its mechanistic underpinnings and critical assay considerations. Gain unique insights into how surface interactions and environmental factors impact its efficacy in oral infection management.

• CXCL1-CXCR2 Signaling Drives Microglial Activation in Pancre

  2026-07-25

  This study elucidates how CXCL1-CXCR2 signaling within the nucleus tractus solitarii (NTS) orchestrates microglial activation, directly contributing to the pathogenesis of pancreatic cancer-induced pain. By integrating transcriptomic, pharmacological, and behavioral approaches, the research identifies a central neuro-immune mechanism with substantial implications for targeted pain therapies.

• Modeling Ceftolozane Resistance in P. aeruginosa via ampC/am

  2026-07-24

  This reference study employs semi-mechanistic PK/PD modeling to quantify how specific ampC and ampD mutations drive ceftolozane-tazobactam resistance and adaptive responses in Pseudomonas aeruginosa. The findings clarify mutation-specific effects on drug efficacy, supporting more precise experimental designs and resistance surveillance strategies.

• Applied Workflows with mCherry mRNA: From Stability to Signa

  2026-07-24

  EZ Cap™ mCherry mRNA (5mCTP, ψUTP) empowers researchers with robust, immune-evasive red fluorescent protein expression. This article translates recent advances in nanoparticle delivery and mRNA engineering into actionable protocols and troubleshooting strategies for molecular tracking, reporter assays, and beyond.

• Multiomics Reveals Bifendate’s Mechanisms in Acute Liver Inj

  2026-07-23

  This study employs a multiomics approach to dissect the molecular mechanisms by which bifendate (DDB) and muaddil sapra treat acute liver injury. The findings highlight bifendate’s specific modulation of ncRNAs and immune-related proteins, providing a deeper understanding of its hepatoprotective action and guiding future clinical and experimental applications.

• Cefiderocol Efficacy Against Resistant Gram-Negative Isolate

  2026-07-23

  This study provides the first large-scale, direct comparison of cefiderocol and multiple β-lactam/β-lactamase inhibitor combinations against European Pseudomonas aeruginosa and Acinetobacter spp., including multidrug-resistant isolates. Findings demonstrate cefiderocol’s superior in vitro activity, informing antibiotic stewardship and susceptibility testing protocols for challenging Gram-negative pathogens.

• Noncompetitive Inhibition of Human PON1 by Phenytoin and AED

  2026-07-22

  This study by Beydemir et al. systematically investigates how widely used anti-epileptic drugs—including phenytoin (5,5-diphenylimidazolidine-2,4-dione)—noncompetitively inhibit human serum paraoxonase-1 (PON1) in vitro. The results establish quantitative inhibition constants, illuminating a potential mechanism for metabolic side effects in epilepsy therapy and providing a robust protocol for enzyme-drug interaction assays.

• Photothermal Therapy and CD47 Blockade Synergy in OSCC

  2026-07-22

  A recent study demonstrates that photothermal therapy (PTT) can significantly enhance the anti-tumor efficacy of CD47 blockade in oral squamous cell carcinoma (OSCC) by inducing immunogenic cell death and altering the tumor extracellular matrix. These findings provide a mechanistic basis for overcoming immune evasion and improving therapeutic responses in solid tumors.

• Antifungal Imidazoles Target CpAdhE in Cryptosporidium parvu

  2026-07-21

  The referenced study identifies antifungal imidazoles as potent inhibitors of the bifunctional aldehyde/alcohol dehydrogenase (CpAdhE) in Cryptosporidium parvum, a key metabolic enzyme in this zoonotic parasite. These findings support CpAdhE as a promising drug target and demonstrate the value of targeted compound screening for anti-cryptosporidial therapy development.

15315 records 1/1021 page Next 12345 下5页 Last page